Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lopinavir/ritonavir - Douglas pharmaceuticals

Drug Profile

Lopinavir/ritonavir - Douglas pharmaceuticals

Alternative Names: R 131

Latest Information Update: 25 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Douglas Pharmaceuticals
  • Class Amides; Antiretrovirals; Carbamates; Pyrimidinones; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cervical intraepithelial neoplasia
  • Phase I Condylomata acuminata; Human papillomavirus infections

Most Recent Events

  • 22 Mar 2019 Phase-I/II clinical trials in Cervical intraepithelial neoplasia in New Zealand (Vaginal) (ACTRN12618001726246p)
  • 26 Oct 2018 Douglas Pharmaceuticals plans a phase I/II trial for Cervical intraepithelial neoplasia in New Zealand (ACTRN12618001726246p)
  • 14 Jun 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top